Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISA...

Full description

Saved in:

Bibliographic Details
Published in:	Euro surveillance : bulletin européen sur les maladies transmissibles Vol. 25; no. 18; p. 1
Main Authors:	Jääskeläinen, Anne J, Kekäläinen, Eliisa, Kallio-Kokko, Hannimari, Mannonen, Laura, Kortela, Elisa, Vapalahti, Olli, Kurkela, Satu, Lappalainen, Maija
Format:	Journal Article
Language:	English
Published:	Sweden Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) 07-05-2020 European Centre for Disease Prevention and Control (ECDC)
Subjects:	Adolescent Adult Aged Aged, 80 and over Antibodies Automation, Laboratory Betacoronavirus Child Child, Preschool Clinical Laboratory Techniques - methods Clinical Laboratory Techniques - standards Coronavirus Infections - diagnosis Coronavirus Infections - epidemiology COVID-19 COVID-19 diagnostic tests COVID-19 Testing Enzyme-Linked Immunosorbent Assay - methods Finland - epidemiology Humans Immunoassay Immunoglobulin A - blood Immunoglobulin G - blood Medical screening Middle Aged Pandemics Pneumonia, Viral - diagnosis Pneumonia, Viral - epidemiology Rapid Communication Reagent Kits, Diagnostic - standards Reproducibility of Results Retrospective Studies SARS-CoV-2 Sensitivity and Specificity Severe acute respiratory syndrome coronavirus 2 Viral infections Young Adult Finland COVID-19 IgG IgA SARS-CoV-2 commercial serology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Antibody-screening methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) need to be validated. We evaluated SARS-CoV-2 IgG and IgA ELISAs in conjunction with the EUROLabworkstation (Euroimmun, Lübeck, Germany). Overall specificities were 91.9% and 73.0% for IgG and IgA ELISAs, respectively. Of 39 coronavirus disease patients, 13 were IgG and IgA positive and 11 IgA alone at sampling. IgGs and IgAs were respectively detected at a median of 12 and 11 days after symptom onset.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Correspondence: Anne J Jääskeläinen (annemarjut.jaaskelainen@hus.fi)
ISSN:	1560-7917 1025-496X 1560-7917
DOI:	10.2807/1560-7917.ES.2020.25.18.2000603